Improving patient access to expensive drugs, paving the way for entry of their cheaper generic equivalents, post patent expiry, and avoiding evergreening, is assuming priority a priority focus area in many countries. The United States is no exception, in this … Continue reading
Tag Archives: CL
How Cost-Effective Are New Cancer Drugs?
The main reason why cancer is so serious a disease, is the ability of the malignant cells to spread in the body, both locally by moving into nearby normal tissue, and regionally to nearby lymph nodes, tissues, or organs, affecting even … Continue reading
At The Indian IPR Front: ‘Ground Control, There’s No Major Storm’
The incessant pressure of the developing countries on India, from 2005 to date, to include various restrictive conditions in the Indian Patents Act 2005, still continue. This demand spans across the inclusion of even those provisions, which many experts term … Continue reading
Ease of Doing Pharma Business in India: A Kaleidoscopic View
Ensuring ease of doing any ethical business activity in India, is a new focus area of the Government and is very rightly so. Creating ease of doing ethical pharma business too, falls under this overall national objective. In this article, … Continue reading
For Drug Safety Concern: “Whistleblower’s Intention Should Be Nationalistic”
In the recent weeks, three significant developments related to the Pharmaceutical Industry in India, have triggered rejuvenated concerns in the following critical areas: A. Overall drug safety standards in the country B. Self serving interest, rather than patients’ interest, dominate … Continue reading
Indian Patents Act To Prevail Undiluted…Finally
Curiously enough, what a little birdie told me just a couple of weeks ago, very similar to that I read in various media reports even less than a week later. It was related to a somewhat trepidatious national policy in the making on … Continue reading
Unsustainable New Cancer Drug Prices: Resolution Remains A Far Cry
Prices of new drugs for the treatment of life-threatening ailments, such as cancer, are increasingly becoming unsustainable, across the world, and more in India. As articulated by the American Society of Clinical Oncology in 2014, this is primarily due to … Continue reading
‘Data Protection’: Needs A Clear Direction…But Is It An IPR Issue?
The terminologies ‘Data Exclusivity’ and ‘Data Protection’ are quite often used interchangeably by many, creating a great deal of confusion on the subject. However, in a true sense these are quite different issues having critical impact on public health interest … Continue reading